['small cell lung carcinoma']
['roniciclib (bay1000394)', 'placebo']

        Inclusion Criteria:

          -  Male or female subjects aged ≥18 years (or country-specific legal age of maturity, if
             >18 years)

          -  Histologically or cytologically confirmed (extensive-stage disease) ED SCLC (small
             cell lung cancer)

          -  At least 1 solid tumor lesion measurable by computer tomography (CT) scan or magnetic
             resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors
             (RECIST) version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1

        Exclusion Criteria:

          -  Prior systemic anticancer therapy for SCLC (including previous therapy with a
             cyclin-dependent kinase [CDK] inhibitor)
      